|Bid||105.32 x 1300|
|Ask||105.41 x 1200|
|Day's Range||105.23 - 105.40|
|52 Week Range||85.37 - 105.40|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.08%|
In 2Q17, BioMarin Pharmaceuticals’ (BMRN) Aldurazyme generated revenues of around $20 million, which was a ~6% increase on a year-over-year (or YoY) basis.
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.
To expand Xyrem’s addressable market, JAZZ has been evaluating the efficacy of Xyrem in pediatric narcolepsy patients with cataplexy and excessive sleepiness.